C a V 1.2 calcium channels respond to small changes in membrane potential to form calcium window, providing sustained influx of Ca 2+ ions to activate vascular smooth muscle contraction.
C a V 1.2 calcium channels respond to small changes in membrane potential to form calcium window, providing sustained influx of Ca 2+ ions to activate vascular smooth muscle contraction. 1, 2 The activity of vascular Ca V 1.2 channels is known to be enhanced in hypertension, which induces increased Ca 2+ ion influx through the Ca V 1.2 channels resulting in greater arterial contractility. Mice deficient in the smooth muscle Ca V 1.2 channel showed the decreased blood pressure. 3 Moreover, the vascular smooth muscle cells (VSMCs) of spontaneously hypertensive rat (SHR) have been shown to produce increased Ca V 1.2 calcium channel functions that contributes to an elevated Ca 2+ influx and development of abnormal arterial tone. 4 However, the mechanisms underlying enhanced activity of vascular Ca V 1.2 channel in hypertension are not well recognized.
As one of post-transcriptional modification mechanisms, alternative splicing (AS) events have been found in the human and rat CACNA1C gene, encoding Ca V 1.2 α1 C subunit. [5] [6] [7] Notably, 2 most extensively alternative exons, exon 9* and 33 have been identified in Ca V 1.2 α1 C of VSMCs, 8, 9 which play a crucial role in differential regulation of several biochemical and biophysical functions of Ca V 1.2 channels, respectively. [9] [10] [11] [12] [13] [14] Moreover, alternative exon 9* of Ca V 1.2 was demonstrated to play an important role in cerebral arterial contraction. 15 Under pathological conditions, such as atherosclerosis, the Ca V 1.2 splicing pattern is changed in arterial smooth muscles, 16 suggesting that the splicing profiles in VSMCs can be dynamically altered in pathological conditions. Furthermore, the splicing patterns of Ca V 1.2 α1 C subunit in cardiac muscles and small resistant arteries Abstract-Calcium influx from activated voltage-gated calcium channel Ca V 1.2 in vascular smooth muscle cells is indispensable for maintaining myogenic tone and blood pressure. The function of Ca V 1.2 channel can be optimized by alternative splicing, one of post-transcriptional modification mechanisms. The splicing factor Rbfox2 is known to regulate the Ca V 1.2 pre-mRNA alternative splicing events during neuronal development. However, Rbfox2's roles in modulating the key function of vascular Ca V 1.2 channel and in the pathogenesis of hypertension remain elusive. Here, we report that the proportion of Ca V 1.2 channels with alternative exon 9* is increased by 10.3%, whereas that with alternative exon 33 is decreased by 10.5% in hypertensive arteries. Surprisingly, the expression level of Rbfox2 is increased ≈3-folds, presumably because of the upregulation of a dominant-negative isoform of Rbfox2. In vascular smooth muscle cells, we find that knockdown of Rbfox2 dynamically increases alternative exon 9*, whereas decreases exon 33 inclusion of Ca V 1.2 channels. By patch-clamp studies, we show that diminished Rbfox2-induced alternative splicing shifts the steady-state activation and inactivation curves of vascular Ca V 1.2 calcium channel to hyperpolarization, which makes the window current potential to more negative. Moreover, siRNA-mediated knockdown of Rbfox2 increases the pressureinduced vascular myogenic tone of rat mesenteric artery. Taken together, our data indicate that Rbfox2 modulates the functions of vascular Ca V 1.2 calcium channel by dynamically regulating the expressions of alternative exons 9* and 33, which in turn affects the vascular myogenic tone. Therefore, our work suggests a key role for Rbfox2 in hypertension, which provides a rational basis for designing antihypertensive therapies. of hypertensive rats are also reported to be altered in comparison with normotensive rats, 17, 18 indicating that Ca V 1.2 alternative exons might be involved in the pathogenesis of hypertension. However, the underlying molecular mechanism of Ca V 1.2 splicing events that precisely regulates the VSMC functions and hypertension is still elusive.
Members of the Rbfox protein family (Rbfox1-3), homologs of the Feminizing on the X gene product from Caenorhabditis elegans, have been long studied for their role in regulating the splicing of many neuron-and muscle-specific splicing events. 19 In mammals, Rbfox1 (A2BP1) is mainly expressed in neurons and muscle tissues. 20, 21 Rbfox2 (RBM9) has varied distribution, 22 whereas Rbfox3 (hnrbp3 or NeuN) is expressed only in mature neurons. 23 Rbfox1-3 proteins share homology in RNA-binding domain that recognizes the hexanucleotide element UGCAUG. 24 In central nervous system, deletion of Rbfox1 or Rbfox2 results in abnormal neuronal excitation of hippocampus and Purkinje cells, respectively. 25, 26 To date, Rbfox2 was reported to be crucial in cardiac development and cardiomyopathies via regulating serial splicing events, [27] [28] [29] [30] [31] indicating a potential role in its regulation of cardiovascular functions. Bioinformatics tools have identified multiple (U)GCAUG elements in the sequence surrounding Ca V 1.2 exons 9* and 33 of different species. By binding to UGCAUG elements, Rbfox2 regulates Ca V 1.2 exons 9* and 33 during neuronal development. 32 Nevertheless, the roles of Rbfox2 in the regulation of vascular Ca V 1.2 splicing and channel function remained unknown.
In this study, we uncovered the unique role of Rbfox2 in hypertension and demonstrated that dysregulated Rbfox2 leads to aberrant splicing of vascular Ca V 1.2 calcium channel, which results in alteration of channel properties attributing to hypertension.
Statistical Analysis
Data are reported as mean±SEM, n number refers to biological repeats. Statistical significance was analyzed using a Student unpaired t test, 1-or 2-way ANOVA followed by post hoc multiple comparisons test. A value of P<0.05 was considered as significant statistical difference.
Results

Rbfox2 Is Expressed in Arterial Smooth Muscle
Rbfox2 has been reported to be expressed in different muscular tissues, including cardiac and skeletal muscle. However, whether it is expressed in vascular smooth muscle is still unclear. To address this issue, we first used reverse transcription-polymerase chain reaction approach by using specific primers (Table S1 in the online-only Data Supplement) to determine that Rbfox2 mRNA was expressed in isolated brain, aorta, Figure 1 . Rbfox2 is expressed at vascular smooth muscle. A, Polymerase chain reaction products were separated on 1% agarose gel; both rat aorta and mesenteric arteries (MAs) contained the product of Rbfox2 mRNA. B, Rbfox2 protein as detected by Western blotting analysis was also observed in the rat aorta and MAs; GAPDH protein was detected as internal control. C, Immunofluorescence staining to determine localization of Rbfox2 in smooth muscles was performed using anti-Rbfox2 antibody (left, 1:100 dilution), and anti-α-smooth muscle actin (middle, 1:100 dilution) in rat MA; the right shows the merged image. VSMC indicates vascular smooth muscle cell.
and mesenteric arteries (MAs) from rats ( Figure 1A ). We also found that Rbfox2 protein was detected in rat aorta and MA by Western blotting ( Figure 1B) . Further, by using immunofluorescence staining, we confirmed the subcellular localization of Rbfox2 mainly in the nucleus of isolated VSMCs ( Figure 1C , top) and MA smooth muscle cells ( Figure 1C , bottom), stained with α-smooth muscle actin, suggesting that Rbfox2 is an RNA-binding protein. These indicated that Rbfox2 in blood vessels might play a crucial in situ function in vascular smooth muscles.
Dysregulation of Rbfox2 and Ca V 1.2 AS in Hypertensive Arteries
Ca V 1.2 alternative exons in VSMCs of hypertensive rats are known to exhibit differential patterns than normotensive rats, 17 which might play a key role in vasotone. Next, we investigated the expression levels of Rbfox2 in orchestration with Ca V 1.2 AS in small resistant arteries. Table S3 showed the baseline characteristics of SHR/Wistar-Kyoto (WKY) rats, such as blood pressure and heart weight-to-body weight ratio. SHR rats exhibited a significantly higher systolic blood pressure and increased heart weight-to-body weight ratio in contrast to age-matched WKY rats. MA tissues were collected from hypertensive or normotensive rats to perform colony reverse transcription-polymerase chain reaction, and we found that the proportion of vascular Ca V 1.2 with alternative exon 9* was increased by 10.3% in the hypertensive MAs from SHR rats ( Figure 2A) . Although, the proportion of vascular Ca V 1.2 with alternative exon 33 was decreased by 10.5% as compared with normotensive arteries from WKY rats ( Figure 2B ). These indicated that the proportion of Ca V 1.2 isoform with inclusion of exon 9* and exclusion of exon 33 (Ca V 1.2 9*,Δ33 ) is critical in hypertensive arteries. Unexpectedly, the expression of Rbfox2 protein in the hypertensive arteries was increased ≈3-folds in comparison with normotensive arteries ( Figure 2C ).
To delineate the underlying mechanism of deregulated Rbfox2 in hypertensive arteries, we examined the expression of the dominant-negative (DN) Rbfox2-a form that excludes exon 6 and only encodes half of the RNA recognition motif ( Figure 2D ). DN Rbfox2 is reported to inhibit the AS activity of wild-type (WT) Rbfox2 because of the low RNA-binding ability and newly gained Rbfox repressor activity. 33 By realtime reverse transcription-polymerase chain reaction, we found that mRNA level of WT Rbfox2 was decreased in the MAs from SHR rats in contrast to WKY rats ( Figure 2E ). However, DN Rbfox2 in the MAs from SHR rats was dramatically increased by ≈2-folds in comparison with WKY rats ( Figure 2F ). These results indicated that the upregulated Rbfox2 protein in hypertensive arteries is attributed to the increased expression of DN isoform. (Table S1 ), the polymerase chain reaction (PCR) products were separated on 2% agarose gel; the upper bands show the inclusion of exon 9* (A, left) or exon 33 (B, left), and the low bands show the exclusion of exon 9* or exon 33. The mesenteric arteries (MAs) from spontaneously hypertensive (SHR) or Wistar-Kyoto (WKY) rats were collected to perform colony PCR (n=200 each rat); the combined data shows the proportion of Ca V 1.2 with exon 9* (A, right) or exon 33 (B, right) in different arterial tissues. C, The expression of Rbfox2 in the rat MAs was detected by Western blotting; GAPDH was detected as loading control. The relative expression of Rbfox2 was normalized to GAPDH. D, Dominant-negative (DN) Rbfox2 is generated by exclusion of exon 6, which encodes half of the RNA recognition motif (RRM). Using specific primers (Table S1 ), we determined wild-type (WT) Rbfox2 (E) or DN Rbfox2 (F) mRNA by real-time reverse transcription-PCR in the MAs from rat; rat Gapdh mRNA was measured as internal control. *P<0.05 versus WKY rats, unpaired t test. December 2017
To further investigate the DN Rbfox2 expression in a cellbased model, we used the mediators of hypertension, such as angiotensin II, endothelin-1, and phenylephrine, to apply to VSMCs. Treatment with angiotensin II ( Figure S1A and S1B) or endothelin-1 ( Figure S1D and S1E) for 48 hours significantly downregulated the expression of Rbfox2 protein and WT Rbfox2 mRNA. However, treatment with phenylephrine increased the Rbfox2 protein and WT Rbfox2 mRNA ( Figure  S1G and S1H), implying a differential pharmacological effect in regulating Rbfox2. Importantly, the expression of DN Rbfox2 mRNA was significantly increased after application with angiotensin II (Figure S1C ) or endothelin-1 ( Figure S1F ) but decreased after application with phenylephrine ( Figure  S1I ). These data indicated that Rbfox2 is indeed dysregulated in the hypertensive VSMCs, suggesting that dysregulated Rbfox2 plays a role in hypertension, and it might regulate AS of vascular Ca V 1.2 in VSMCs.
Rbfox2 Dynamically Regulates AS of Ca V 1.2 Calcium Channel in VSMCs
Rbfox proteins were found to regulate Ca V 1.2 AS in the neuronal development; 32 however, its role in the AS events of vascular Ca V 1.2 channel remains unknown. To explore the underlying molecular mechanism of Rbfox2 that regulates the AS events of Ca V 1.2 channel in VSMCs, we used siRNA approach to specifically knockdown the endogenous expression of Rbfox2 in VSMCs with high efficiency (Figures S2A  and S3A; Table S2 ). In addition, specific primers were used to identify the percentage of alternative exon 9* or 33 of Ca V 1.2 channels from VSMCs. The amplified products were assessed on the basis of differential migration patterns on 2% to 3% agarose gel ( Figure 3A) . In nontreated or nontargeting siRNAtransfected VSMCs, ≈40% Ca V 1.2 channels included exon 9*, and ≈50% Ca V 1.2 channels included exon 33, which lies in agreement with the previous findings. 9, 11, 12 However, knockdown of Rbfox2 in isolated VSMCs resulted in an increase by ≈10.8% of Ca V 1.2 with exon 9* inclusion ( Figure 3B ), whereas decrease by ≈15.3% of Ca V 1.2 with exon 33 inclusion ( Figure 3C ). Moreover, Rbfox2 knockdown in A7r5 cells showed significantly increased proportion of Ca V 1.2 with exon 9* ( Figure S2B and S2D), whereas produced decreased proportion of Ca V 1.2 with exon 33 ( Figure S2B and S2E). On the contrary, the expression of Rbfox2 homolog, Rbfox1, remained unchanged after treatment with Rbfox2 siRNA in Figure 3 . siRNA-mediated knockdown of Rbfox2 increases the proportion of Ca V 1.2 with exon 9* and decreases that with exon 33 in vascular smooth muscle cells (VSMCs). A, Schematic diagram shows the locations of the polymerase chain reaction (PCR) primers designed to amplify and detect rat Ca V 1.2 inclusive of or in the absence of exon 9* or 33 in VSMCs. Isolated VSMCs were transfected with nontargeting (NT) or Rbfox2 siRNA; nontreated cells were set as negative control (NC). After 48-h incubation, the endogenous expression of Rbfox2 protein was detected by Western blotting, the α-smooth muscle actin was detected as internal control. PCR products amplified from cDNA libraries of differentially treated VSMCs were separated on 2% to 3% agarose gel. Gapdh mRNA was detected as internal control. The values for percent exon 9* (B) or exon 33 (C) inclusion were the upper band intensity divided by the summed intensities of upper and lower bands. The results were from 5 independent experiments. D, VSMCs were transfected with vector or Rbfox2 plasmid, nontreated cells were set as NC. After 48-h incubation, the expression of Rbfox2 protein was detected by Western blotting, PCR products were separated on 2% to 3% agarose gel. The values for percent exon 9* (E) or exon 33 (F) inclusion were analyzed and presented as bar charts. The results were from 3 independent experiments. *P<0.05, **P<0.01 versus NT siRNA-treated or vector-transfected VSMCs, 1-way ANOVA followed by a Newman-Keuls method for post hoc pairwise multiple comparisons. FP indicates forward primer; RP, reverse primer; RT, reverse transcription; and WB, Western blotting.
A7r5 cells, indicating Rbfox2 knockdown does not induce the compensatory expression of Rbfox1 ( Figure S2B and S2C) . Consistently, Rbfox2 knockdown induced similar effects on the expression of alternative exons 9* and 33 of Ca V 1.2 channels in MA smooth muscle cells ( Figure S3 ).
In contrast to the effect induced by siRNA-mediated Rbfox2 knockdown, its overexpression suppressed the inclusion of exon 9* in Ca V 1.2 channels (Figure 3D and 3E) , whereas activated the inclusion of exon 33 in isolated VSMCs ( Figure 3D and 3F) . Notably, coexpression of DN Rbfox2 abolished the effects of overexpressed WT Rbfox2 on the regulation of Ca V 1.2 exons 9* and 33 in VSMCs (Figure S4 ), which was in line with previous report. 33 Together, our results indicated that Rbfox2 dynamically regulates the AS of Ca V 1.2 channel in VSMCs, and aberrant splicing of Ca V 1.2 is indeed attributed to dysregulated Rbfox2 in hypertensive arteries.
Aberrant Splicing in Hypertensive Arteries Alters Ca V 1.2 Channel Characteristics
To study the relevance of Rbfox2-induced AS in Ca V 1.2 channel of hypertensive arteries, we generated a specific human Ca V 1.2 9*,Δ33 construct by using Ca V 1.2 WT (Ca V 1.2 Δ9*,33 ) construct-a major isoform expressed in blood vessel-as reference channel. 9, 15, 34 Stepwise voltage stimulation was used to evaluate current-voltage (I-V) relationships in heterologously expressed human embryonic kidney-293 cells. As shown in Figure 4A and Table S4 , the I-V curve of Ca V 1.2 9*,Δ33 shifted toward left (hyperpolarized) with ≈5-mV peak current. Moreover, V 0.5 (half-activation potential) was also hyperpolarized ≈3 mV, in comparison with Ca V 1.2 Δ9*,33 construct, suggesting the inclusion of exon 9* and the exclusion of exon 33 in Ca V 1.2 calcium channel can result in hyperpolarization of calcium channels and thus affect channel activation or inactivation properties, or both.
To determine the detailed electrophysiological properties in different alternatively spliced Ca V 1.2 channels, we used 2 different protocols to measure the steady-state activation and inactivation curves, respectively. As shown in Figure 4B and Table S5 , the activation curve and V 0.5 of Ca V 1.2 9*,Δ33 were shifted toward hyperpolarized potential, suggesting that the Ca V 1.2 9*,Δ33 channels could be more easily opened on depolarization from resting membrane potential. Additionally, the inactivation curve ( Figure 4C ) and V 0.5,inact (half-inactivation potential; Table S5 ) of Ca V 1.2 9*,Δ33 was also hyperpolarized. Notably, these results were in line with the previous findings on the electrophysiological properties of 1 Ca V 1.2 channel isoform in myocardial infarction. 35 Moreover, the window current of Ca V 1.2 9*,Δ33 , superimposed from steady-state activation and inactivation curves, was shifted toward hyperpolarization as against to Ca V 1.2 Δ9*,33 ( Figure 4D and 4E), indicating that the opening and inactivation potential of Ca V 1.2 9*,Δ33 is closer to the resting membrane potential. However, the current densities of these 2 Ca V 1.2 constructs were insignificant ( Figure  S5 ), indicating that Ca V 1.2 9*,Δ33 might upregulate the channel (black) or Ca V 1.2 9*,Δ33 (gray) were activated by a family of 6-ms test pulses first, ranging from −70 to 100 mV, and tail currents to −50 mV were measured lastly (Tail protocol). Each tail current was normalized to the peak one. Plots of steady-state activation (SSA) curve were analyzed from tail currents. C, Steady-state inactivation (SSI) of Ca V 1.2 Δ9*,33 (black) or Ca V 1.2 9*,Δ33 (gray) was recorded by SSI protocol, briefly the cells were depolarized from a 30-ms normalization pulse to 10 mV followed by a family of 5-s long pulses ranging from −80 to 20 mV. A final 104-ms test pulse to 10 mV was applied, the holding potential between pulses was −90 mV. Each test pulse was normalized to the peak current of the normalizing pulse. D, The calcium window currents were superimposed from SSI (f ∞ ) and SSA (d ∞ ) curves of Ca V 1.2 Δ9*,33 (black) or Ca V 1.2 9*,Δ33 (gray) channel. E, Enlarged plots of calcium window currents of different Ca V 1.2 channels. activity without affecting calcium channel current densities. Furthermore, calcium-dependent inactivation ( Figure S6 ), channel decay ( Figure S7 ), and rate of recovery from inactivation ( Figure S8 ; Table S5 ) of the channel remained unchanged. Taken together, our data indicated that the inclusion of exon 9* with exclusion of exon 33 in Ca V 1.2 channel exclusively affects the channel kinetics, including channel activation and inactivation.
siRNA-Mediated Knockdown of Rbfox2 Hyperpolarizes the Window Current of Ca V 1.2 in VSMCs
We have measured channel properties produced by a single variant of Ca V α1 C and a defined set of auxiliary subunits in a heterologous system of human embryonic kidney-293 cells. However, it cannot fully demonstrate the arterial myocyte currents because of the combination of different splice variants and different subunits of Ca V 1.2. Therefore, we examined the direct effects of Rbfox2 on native vascular Ca V 1.2 channel function in a more physiologically relevant system. To this end, we used whole-cell patch-clamp recording in isolated native VSMCs, the results showed that the steadystate activation (Figure 5A and 5B; Table S6 ) and inactivation curves (Figure 5C and 5D; Table S6 ) shifted to more negative post-Rbfox2 knockdown in VMSCs, respectively. Moreover, the potential at peak window currents was hyperpolarizedshifted ≈7 mV after knockdown of Rbfox2 ( Figure 5E and 5F). However, the current density ( Figure S9 ) and the rate of recovery from inactivation ( Figure S10 ; Table S6 ) of Ca V 1.2 channel did not change after knockdown of Rbfox2 in isolated VSMCs, which was consistent with the electrophysiological properties recorded from human Ca V 1.2 9*,Δ33 channels expressed in human embryonic kidney-293 cells. Together, our findings indicated that Rbfox2 directly affects the Ca V 1.2 channel properties in VSMCs via regulating AS of Ca V 1.2 channels.
Rbfox2 Regulates Intraluminal Pressure-Induced Arterial Myogenic Tone
Ca V 1.2 calcium channel is known to play an integral role in the maintenance of vascular constriction and myogenic tone.
13,36 Therefore, we hypothesized that Rbfox2 may play a role in arterial vasotone by precisely regulating the function of vascular Ca V 1.2 channel. After Rbfox2 siRNAmediated reversible permeabilization for 72 hours, endogenous expression of Rbfox2 was significantly decreased in the rat MAs ( Figure 6A ), but the membrane expression of Ca V 1.2 α1 C subunit remained unchanged ( Figure S11 ). Subsequently, vascular myogenic tone was induced as a result of increased intraluminal pressures by using the Living System. 36 Reversible permeabilized arteries transfected with Rbfox2 siRNA resulted in increased pressure-induced myogenic tone in comparison with nontargeting siRNA-treated MAs ( Figure 6B and 6C) . Therefore, our data indicated that knockdown of Rbfox2 upregulates Ca V 1.2 channel activity, but not its surface expression, resulting in vasoconstriction of the MAs. This implies Rbfox2 protein might be crucial in the regulation of blood pressure via modulating vascular myogenic tone.
Discussion
Tight regulation of Ca 2+ ions influx via Ca V 1.2 channels plays crucial roles in diverse physiological mechanisms, including excitation-contraction coupling in small resistant arteries. 37, 38 Presently, AS has emerged as an important post-transcriptional mechanism providing a new dimension to precise regulation of Ca V 1.2 channel activity in response to diverse signals or stimuli. Evidences have related dysfunctions in alternative exons in Ca V 1.2 channel to chronic diseases like chronic myocardial infarction and cardiac hypertrophy. 35, 39 However, it is still intriguing whether and how Ca V 1.2 AS is dynamically regulated in the pathophysiology of vascular myogenic tone and blood pressure. By addressing these issues, we have first found that the proportion of Ca V 1.2 channels with alternative exon 9* is increased, whereas that with alternative exon 33 is decreased in hypertensive arteries. However, Rbfox2 protein expression is paradoxically elevated, which is attributed to the increased expression of DN Rbfox2. Our results also indicated that Rbfox2 dynamically regulates the expressions of alternative exons 9* and 33 of Ca V 1.2 channel in VSMCs, and this effect could be inhibited by DN Rbfox2. Notably, knockdown of Rbfox2 results in hyperpolarized shift of calcium channel window current and increases vascular myogenic tone ( Figure 6D ). Together, these observations suggested that Rbfox2 could play a pivotal role in the pathogenesis of hypertension.
In heart, the expression of Rbfox2 was found to be downregulated on overloaded pressure, whereas Rbfox2 knockout generated the decompensatory heart failure in mice. 31 As Rbfox protein is crucial in the AS of Ca V 1.2 exons 9* and 33, we initially thought that the aberrant exons 9* and 33 in hypertensive arteries might be because of the decreased Rbfox2 expression. Surprisingly, the expression of Rbfox2 in hypertensive arteries was found in our work to be dramatically increased ≈3-folds in comparison with normotensive arteries, which is attributed to the increased expression of DN Rbfox2 ( Figure 2C through 2F ). This observation is in close agreement with the previous report, which indicated that the expression of Rbfox2 also increased ≈4-folds in human type 2 diabetic cardiomyopathy but with low Rbfox2 activity because of the presence of DN Rbfox2. 30 Moreover, the mediators of hypertension, such as angiotensin II and endothelin-1, induce the expression of DN Rbfox2 with decreased WT Rbfox2 in VSMCs, implying Rbfox2 could also be regulated by hormonal stimuli in hypertension. Nevertheless, its detailed mechanisms remain to be further investigated.
Multiple Rbfox-binding elements (UGCAUG) have been identified surrounding exon 9*, whereas only one site is located at downstream of exon 33. 32 Because the effects of splicing factors are dependent on the position (upstream or downstream of cassette exon) of binding elements, Rbfox proteins have been proved to play differentially regulatory effects on exons 9* and 33 of Ca V 1.2 channel in the development of cortical neurons. 32 In our study, Ca V 1.2 with exon 9* was increased and that with exon 33 was decreased after knockdown of Rbfox2, indicating Rbfox2 represses exon 9* and activates exon 33 of Ca V 1.2 in VSMCs, consistent with previous findings in neural cells. 32 Our data also indicated the proportion of Ca V 1.2 channels with exon 9* is increased, whereas that with exon 33 is decreased in hypertensive arteries, similar to the changes of Ca V 1.2 splicing patterns in hypertension-induced cardiac hypertrophy 18 and chronic myocardial infarction. 35 Because DN Rbfox2 inhibited the effects of WT Rbfox2 on the regulation of Ca V 1.2 exons 9* and 33 in VSMCs, the increased proportion of Ca V 1.2 channels with exon 9* and the decreased proportion of Ca V 1.2 channels with exon 33 was believed to be owed to the upregulated DN Rbfox2 in hypertensive arteries. Because dysregulated Rbfox was also found in the diseased hearts, [29] [30] [31] whether Rbfox is a crucial regulator of Ca V 1.2 AS in the cardiac hypertrophy and myocardial infarction remains largely unknown. Unraveling this precise molecular mechanism may lead to more efficacious managements for cardiomyopathies.
Alternative exon 9* or 33 could affect electrophysiological properties of Ca V 1.2 calcium channels expressed in human embryonic kidney-293 cells. 8, 9 For example, inclusion of exon 9* in Ca V 1.2 calcium channels hyperpolarized-shifted channel activation, 9 possibly attributed to conformational changes in the endoplasmic reticulum export signaling region of Ca V α1 C I-II loop, the binding site of Ca V β subunits. 13, 40 On the contrary, exclusion of exon 33 in Ca V 1.2 calcium channel also resulted in hyperpolarized shift of voltage-dependent activation, 8, 14 possibly owing to the structural changes in voltage sensor of Ca V 1.2 channels. Here, we demonstrated that hypertensive arteries exhibit increased expression of Ca V 1.2 9*,Δ33 isoform and also showed this channel hyperpolarized shifts (left shift) I-V, steady-state activation, and inactivation curves in comparison with vascular Ca V 1.2 Δ9*,33 channel. It is noteworthy that VSMCs from hypertensive arteries also showed hyperpolarized shift of I-V curve in comparison with normotensive arteries, 17 suggesting the changes of Ca V 1.2 electrophysiological kinetics in hypertensive smooth muscle cells might be because of the increased expression of Ca V 1.2 9*,Δ33 channels. Further, our results indicated that knockdown of Rbfox2 shifts the calcium window current potential to more negative in isolated VSMCs. These data revealed that Rbfox2 directly modulates the function of vascular Ca V 1.2 channel by regulating the combination of alternative exons 9* and 33 in VSMCs. Ca V 1.2 channels, shifting to hyperpolarization, could be activated more readily close to the resting membrane potential of smooth muscles, which may play a significant role in the pathogenesis of hypertension.
Vascular myogenic tone is an important intrinsic mechanism regulating blood flow during changes in perfusion pressure, 41 and the vasotone responding to the intraluminal pressure is mediated by activating Ca V 1.2 channels. 42 Several evidences have demonstrated that enhanced activity of vascular Ca V 1.2 channel leads to irregular myogenic responses and induction of hypertension. 43 Our study indicated that siRNA-mediated knockdown of Rbfox2 in rat MAs causes increased intraluminal pressure-induced vascular myogenic tone, attributed to leftward shift of window current of Ca V 1.2 channel in VSMCs. Although we cannot exclude the possibility of splicing events of other target genes (including voltage-gated sodium, potassium channels, and calmodulin 25 ) controlled by Rbfox2 in the regulation of vasotone, our data illustrated that Rbfox2-mediated AS in vascular Ca V 1.2 channel is indeed important to maintain vascular myogenic tone and hypertension.
Perspectives
Although it has been known that enhanced activities of vascular Ca V 1.2 calcium channel are tightly associated with hypertension, the underlying molecular mechanisms remain unknown. 44 The current study indicates that Rbfox2 works as a regulator of Ca V 1.2 AS and channel function in vascular smooth muscle, suggesting Rbfox2 may play a crucial role in hypertension via regulating AS of Ca V 1.2. Reasonably, Rbfox2 can be used to reset the aberrant splicing and function of vascular Ca V 1.2 channel, and in vivo manipulation of Rbfox2 in vascular smooth muscles might modulate vascular myogenic tone, and regulate blood pressure. Therefore, this work might provide a rational basis for designing antihypertensive therapies.
